SGLT2 inhibitors vs placebo
Hypoglycaemia requiring third‐party assistance median · people with diabetes and CKD
Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors leads to lower hypoglycaemia requiring third‐party assistance median compared with placebo (high certainty).
1 finding from 1 review
- Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes 2024 · Cochrane Headline outcomes onlyRR 0.75 [0.65, 0.88]14 studies · 26478 participantsHigh